tMoA

Would you like to react to this message? Create an account in a few clicks or log in to continue.
tMoA

~ The only Home on the Web You'll ever need ~

2 posters

    SAGE report: esearch and analysis Long term evolution of SARS-CoV-2, 26 July 2021 Paper prepared by academics on the viral evolution of COVID-19.

    mudra
    mudra


    Posts : 22369
    Join date : 2010-04-09
    Age : 67
    Location : belgium

    SAGE report: esearch and analysis Long term evolution of SARS-CoV-2, 26 July 2021 Paper prepared by academics on the viral evolution of COVID-19. Empty SAGE report: esearch and analysis Long term evolution of SARS-CoV-2, 26 July 2021 Paper prepared by academics on the viral evolution of COVID-19.

    Post  mudra Wed Aug 04, 2021 2:05 pm


    GOV.UK

    Research and analysis

    Long term evolution of SARS-CoV-2, 26 July 2021
    Paper prepared by academics on the viral evolution of COVID-19.

    From : SAGE
    Scientific Advisory Group For Emergencies


    ( note: computer modelling )



    Details

    Paper presented by group of academics on scenarios for the longer term evolution of SARS-CoV-2. It was considered at SAGE 94 on 22 July 2021 and updated on 26 July 2021.

    The paper is the assessment of the evidence at the time of writing. As new evidence or data emerges, SAGE updates its advice accordingly.

    These documents are released as pre-print publications that have provided the government with rapid evidence during an emergency. These documents have not been peer-reviewed and there is no restriction on authors submitting and publishing this evidence in peer-reviewed journals.

    Published 30 July 2021

    Can we predict the limits of SARS-CoV-2 variants and their phenotypic consequences?
    As eradication of SARS-CoV-2 will be unlikely, we have high confidence in stating that there will always be variants. The number of variants will depend on control measures.
    We describe hypothetical scenarios by which SARS-CoV-2 could further evolve and acquire, through mutation, phenotypes of concern, which we assess according to possibility. For this purpose, we consider mutations in the ‘body’ of the virus (the viral genes that are expressed in infected cells and control replication and cell response), that might affect virus fitness and disease severity, separately from mutations in the spike glycoprotein that might affect virus transmission and antibody escape.
    We assess which scenarios are the most likely and what impact they might have and consider how these scenarios might be mitigated. We provide supporting information based on the evolution of SARS-CoV-2, human and animal coronaviruses as well as drawing parallels with other viruses.

    Scenario One:

    A variant that causes severe disease in a greater proportion of the population than has occurred to date. For example, with similar morbidity/mortality to other zoonotic coronaviruses such as SARS-CoV (~10% case fatality) or MERS-CoV (~35% case fatality). This could be caused by:
    1. Point mutations or recombination with other host or viral genes. This might occur through a change in SARS-CoV-2 internal genes such as the polymerase proteins or accessory proteins. These genes determine the outcome of infection by affecting the way the virus is sensed by the cell, the speed at which the virus replicates and the anti-viral response of the cell to infection. There is precedent for Coronaviruses (CoVs) to acquire additional genes or sequences from the host, from themselves or from other viruses.
    2. By recombination between two VOC or VUIs. One with high drift (change in the spike glycoprotein) from the current spike glycoprotein gene used in the vaccine and the other with a more efficient replication and transmission determined by internal genes, for example, a recombination between beta and alpha or delta variants respectively. Alternatively, recombination may occur between two different variants with two different strategies for overcoming innate immunity, combining to give an additive or synergistic change of phenotype resulting in higher replication of the virus – and potentially increased morbidity and mortality.
    Likelihood of genotypic change in internal genes: Likely whilst the circulation of SARS- CoV-2 is high.
    Likelihood of increased severity phenotype: Realistic possibility.
    Impact: High. Unless there is significant drift in the spike glycoprotein gene sequence, then the current spike glycoprotein-based vaccines are highly likely to continue to provide protection against serious disease. However, an increase in morbidity and mortality would be expected even in the face of vaccination since vaccines do not provide absolute sterilising immunity i.e. they do not fully prevent infection in most individuals.
    What can we do?

    • Consider vaccine booster doses to maintain protection against severe disease.
    • Reduce transmission of SARS-CoV-2 within the UK (to reduce risk of point
    mutations, recombination).
    • Minimise introduction of new variants from other territories (to reduce risk of
    recombination between variants).
    • Targeted surveillance for reverse zoonoses, and if necessary, consider animal
    vaccination, slaughter, or isolation policies.
    • Continue to monitor disease severity associated with variants (to identify
    changes in phenotype).
    • Continue to develop improved prophylactic and therapeutic drugs for SARS-
    CoV-2 and disease symptoms.
    • Consider stockpiling prophylactic and therapeutic drugs for SARS-CoV-2.

    Scenario Two:

    A variant that evades current vaccines. This could be caused by:
    3. Antigenic ‘shift’: Natural recombination events that insert a different spike gene sequence (or partial sequence) from human CoVs MERS-CoV (highly unlikely due to the low frequency of MERS-CoV infections), or from currently circulating endemic human CoVs (more likely due to the prevalence of these viruses). This would recombine into the ‘body’ of SARS-CoV-2 that is capable of high replication in human cells. The consequence could be a virus that causes disease at a level similar to COVID-19 when it first emerged but against which our current battery of spike glycoprotein-based vaccines would not work.
    Likelihood: Realistic possibility.
    Impact: High for a completely new spike, medium/low if a spike from a seasonal CoV is introduced since we expect a proportion of the population to have antibodies to these endemic viruses.
    What could we do? In the case of introduction of a completely different spike glycoprotein, a similar vaccine platform could be rapidly employed as has been used successfully on the original Wuhan SARS-CoV-2 and subsequent variants. However, there would be a time lag for roll out whilst these vaccines were generated in sufficient quantities to control and mitigate the effects of infection.
    4. A longer-term version of shift whereby SARS-CoV-2 undergoes a reverse zoonotic event into an animal reservoir(s). This virus is then on a separate evolutionary trajectory because the virus animals is subject to different selection processes than in humans. The SARS-CoV-2 decedents then re-emerge into humans at a later time when vaccines that have been updated to keep pace with drift in humans sufficiently mismatched so as not able to provide immunologic cross protection.
    Likelihood: Realistic possibility. Impact: Medium.
    What could we do? Maintain a capacity to make vaccines with updated/different spike protein variants and begin to develop broader CoV immunity in the human population to diverse coronaviruses. For example, begin to develop a universal coronavirus vaccine with strong cross protection to other CoVs potentially using other viral proteins rather than just the spike glycoprotein.
    5. Antigenic drift: A gradual or punctuated accumulation of antigenic variation that eventually leads to current vaccine failure. Worst case is that this drift combines with significant antigenic sin (vaccination resulting in an immune response that is dominated by antibodies to previously experienced viruses/vaccines) meaning that it becomes difficult to revaccinate to induce antibodies to the new strains. Genetic and antigenic drift are almost inevitable. Antigenic sin has not yet been reported for SARS-CoV-2 so we consider this possibility less likely.
    Likelihood: Almost certain. Impact: Medium.

    What could we do? Need to continue vaccinating vulnerable age groups at regular periods with updated vaccines to the dominant antigenic drift variants to increase an individual’s immunological protection against SARS-CoV-2 variants.
    • Monitor antigenic variants and update candidate vaccines to cover antigenic escape variants.
    • Conduct clinical trials of re-vaccination with antigenically distant vaccines
    • Consider clinical trials of multi-valent vaccines.
    • Re-vaccinate vulnerable age groups at regular periods with updated vaccines to
    the dominant antigenic drift variants to increase an individual’s immunological
    landscape to SARS-CoV-2 variants.
    • Reduce transmission of SARS-CoV-2 within the UK (to reduce risk of point
    mutations, recombination).
    • Minimise introduction of new variants from other territories (to reduce risk of
    recombination between variants).
    • Monitor for reverse zoonoses and if necessary, consider animal vaccination,
    slaughter, or isolation policies.
    • Continue to develop improved prophylactic and therapeutic drugs for SARS-
    CoV-2.
    • Stockpile prophylactic and therapeutic drugs for SARS-CoV-2.

    ... read all: https://www.gov.uk/government/publications/long-term-evolution-of-sars-cov-2-26-july-2021
    mudra
    mudra


    Posts : 22369
    Join date : 2010-04-09
    Age : 67
    Location : belgium

    SAGE report: esearch and analysis Long term evolution of SARS-CoV-2, 26 July 2021 Paper prepared by academics on the viral evolution of COVID-19. Empty Re: SAGE report: esearch and analysis Long term evolution of SARS-CoV-2, 26 July 2021 Paper prepared by academics on the viral evolution of COVID-19.

    Post  mudra Wed Aug 04, 2021 2:32 pm

    MASSIVE DEATH TOLL AHEAD! - UK GOVERNMENT PREDICTS 1 IN 3 PEOPLE WILL DIE! - MAJORITY WITH VACCINE?

     https://www.bitchute.com/video/TUZVirYRJRFJ/


    Poster: World Alternative Media (WAM)
    Vidya Moksha
    Vidya Moksha


    Posts : 1174
    Join date : 2010-04-16
    Location : on the road again :)

    SAGE report: esearch and analysis Long term evolution of SARS-CoV-2, 26 July 2021 Paper prepared by academics on the viral evolution of COVID-19. Empty Re: SAGE report: esearch and analysis Long term evolution of SARS-CoV-2, 26 July 2021 Paper prepared by academics on the viral evolution of COVID-19.

    Post  Vidya Moksha Thu Aug 05, 2021 8:32 am

    I just caught this news. Well, we were asking how many will die from the shot and the banksters have given us their estimate. Though it is just more spurious modelling.

    Whatever. The Irish and Canadian courts have failed to prove evidence that covid-19 even exists.. it was never isolated. Will this information snowball? Certainly not in bankster media.

    The banksters have their intent. It is a known fact that mutations always get weaker, not stronger. (lab created ones excepted). But there is no covid anyway. Its just the next stage of their plan. They are letting us know to prepare for billions of deaths. All will be mRNA jab related.

    oh.. and those suicided trying to expose the illusion.
    mudra
    mudra


    Posts : 22369
    Join date : 2010-04-09
    Age : 67
    Location : belgium

    SAGE report: esearch and analysis Long term evolution of SARS-CoV-2, 26 July 2021 Paper prepared by academics on the viral evolution of COVID-19. Empty Re: SAGE report: esearch and analysis Long term evolution of SARS-CoV-2, 26 July 2021 Paper prepared by academics on the viral evolution of COVID-19.

    Post  mudra Thu Aug 05, 2021 6:13 pm

    Yes Vidya and  pets won't be spared in the process if I read well between the lines as well as  farm animals. Regarding the latest thats how the fake meat agenda comes on the scene i guess.
    I read somewhere they can now make edible protein out of plastic 😳
    What a bright future we are moving into.

    https://mistsofavalon.forumotion.com/t10353-invention-uses-microbes-to-convert-plastic-waste-into-edible-protein-but-would-you-eat-it?highlight=Meat+made+out+of+plastic
    Vidya Moksha
    Vidya Moksha


    Posts : 1174
    Join date : 2010-04-16
    Location : on the road again :)

    SAGE report: esearch and analysis Long term evolution of SARS-CoV-2, 26 July 2021 Paper prepared by academics on the viral evolution of COVID-19. Empty Re: SAGE report: esearch and analysis Long term evolution of SARS-CoV-2, 26 July 2021 Paper prepared by academics on the viral evolution of COVID-19.

    Post  Vidya Moksha Fri Aug 06, 2021 3:45 am

    if all the global pandemics were caused by electromagnetic poison then the 'deadly' variant, whatever name they give it, will be the cover story for the billions who die from switching on 5G.
    The next variant will be blamed for killing those that have taken the mRNA poison.
    when does elon musk switch on skynet and beam 5G to the world? That's when the big virus scare hits the world.

    https://www.youtube.com/watch?v=k90VVhyM8Ss

    mudra
    mudra


    Posts : 22369
    Join date : 2010-04-09
    Age : 67
    Location : belgium

    SAGE report: esearch and analysis Long term evolution of SARS-CoV-2, 26 July 2021 Paper prepared by academics on the viral evolution of COVID-19. Empty Re: SAGE report: esearch and analysis Long term evolution of SARS-CoV-2, 26 July 2021 Paper prepared by academics on the viral evolution of COVID-19.

    Post  mudra Fri Aug 06, 2021 9:39 am

    Yes Vidya 5G, 6G its already happening

    Shaping Europe digital future

    5G

    5G provides virtually universal, ultra-high bandwidth, and low latency "connectivity" not only to individual users but also to connected objects. It is expected to serve a wide range of applications and sectors including professional uses. For example, connected automated mobility, eHealth, energy management, possibly safety applications, and more.

    5G will also be a key enabler of artificial intelligence systems, as it will provide real-time data collection and analysis. At the same time, it will bring the cloud to a new dimension by enabling the distribution of computing and storage, such as edge cloud, and mobile edge computing, throughout the infrastructure,

    Europe shaping the 5G vision

    The European Commission identified 5G opportunities early, establishing a public-private partnership on 5G (5G-PPP) in 2013 to accelerate research and innovation in 5G technology. The European Commission has committed public funding of more than €700 million through the Horizon 2020 Programme to support this activity.

    These activities are accompanied by an international plan to ensure global consensus building on 5G. EU investment in 5G research and standards is necessary to support the traffic volume expected by 2025. EU investment will also boost networks and Internet architectures in emerging areas such as machine-to-machine (M2M) communication and the Internet of Things (IoT).

    The Commission adopted a 5G action plan for Europe in 2016 to ensure the early deployment of 5G infrastructure across Europe. The objective of the action plan was to start launching 5G services in all EU Member States by end 2020 at the latest. Following this, it suggests a rapid build-up to ensure uninterrupted 5G coverage in urban areas and along main transport paths by 2025.

    https://digital-strategy.ec.europa.eu/en/policies/5g



    And by the way I found a link between graphene and 5G
    https://www.mdpi.com/1424-8220/19/22/4835


    Last edited by mudra on Fri Aug 06, 2021 9:53 am; edited 2 times in total
    mudra
    mudra


    Posts : 22369
    Join date : 2010-04-09
    Age : 67
    Location : belgium

    SAGE report: esearch and analysis Long term evolution of SARS-CoV-2, 26 July 2021 Paper prepared by academics on the viral evolution of COVID-19. Empty Re: SAGE report: esearch and analysis Long term evolution of SARS-CoV-2, 26 July 2021 Paper prepared by academics on the viral evolution of COVID-19.

    Post  mudra Fri Aug 06, 2021 9:45 am

    5gobservatory EU



     As 5G is gearing up for market deployment, the European 5G Observatory provides updates on all of the latest market developments, including actions being undertaken by the private and public sectors, in the field of 5G. The 5G observatory also delivers an analysis of the strategic implications of the 5G Action Plan and other public policy objectives.

    The Observatory focuses on 5G developments in Europe, along with major international developments (USA, Japan, China, South Korea) that could impact the European market.

    https://5gobservatory.eu/


    3G / 4G / 5G coverage map

    https://www.nperf.com/en/map/BE/-/-/signal/?ll=50.510588799271936&lg=4.474999999999981&zoom=7

      Current date/time is Sat Jan 22, 2022 9:41 am